Pay in 4 interest-free payments of $5.63 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
In that trial, Mounjaro produced 20.2% weight loss compared with 13.7% for semaglutide 2.4 mg over 72 weeks
The most frequent adverse effects are gastrointestinal and dose-related: Nausea, vomiting, diarrhoea, constipation, and abdominal discomfort - Typically worst during dose escalation and often resolve or attenuate with continued treatment and slower titration
By activating both GLP-1 and GIP, Zepbound has been shown to lead to even greater weight loss in some individuals
Participants receiving semaglutide showed nearly a 50% reduction in alcohol consumptionan effect size equal to or greater than seen with FDA-approved medications for AUD, like naltrexone, acamprosate, and disulfiram
Weight loss was initially observed as a side effect of GLP-1 medications in clinical trials testing the drugs for type 2 diabetes
US$ 21.42
US$ 29.79
US$ 20.58
US$ 26.97
US$ 27.02
US$ 22.29
US$ 29.31
US$ 25.89
US$ 28.04
